Ebola Travel Rules, H1N1 Arrives Early, and NEJM on PKU Drug and Superbugs

Saturday's health roundup covers five developments: a new US air-travel rule tied to the Ebola outbreak in the Democratic Republic of the Congo, an early and above-normal start to the 2026–27 influenza season driven by a mutated H1N1 strain, a phase 2 trial in the New England Journal of Medicine showing a new oral drug substantially lowers phenylalanine in phenylketonuria, an NEJM review placing gram-negative antimicrobial resistance in sharp focus, and an FDA decision pending this quarter on a novel stroke-prevention anticoagulant.

Saturday, 1 November: CDC Ebola Attestation Hits All US-Bound Flights on Sunday

From 11:59 p.m. Eastern Time on Sunday 3 November 2026, every passenger boarding any flight to a US destination — including US citizens and nationals — must sign a CDC attestation confirming they have not been in the Democratic Republic of the Congo during the preceding 21 days. The order, issued 22 October by the Centers for Disease Control and Prevention, is scheduled to expire on 18 December 2026 unless amended. It covers commercial, general aviation, cargo, and private aircraft; land border crossings and sea ports are not affected.

Airlines must retain completed forms for at least 42 days after arrival, and false attestations expose passengers to prosecution and civil fines. Airlines for America and IATA have challenged the rollout pace, citing difficulties integrating the requirement across international networks; as of Saturday no delay has been publicly confirmed.

The order responds directly to the Bundibugyo virus Ebola outbreak in the DRC, which now exceeds 10,000 confirmed cases and approximately 5,000 confirmed deaths — the second-largest Ebola outbreak in recorded history after West Africa 2013–16. Cases genomically linked to the DRC lineage have appeared in Nigeria and Kenya through international travel. On a contrasting note, WHO and Africa CDC jointly declared Uganda's separate Bundibugyo outbreak over on 27 October, having contained 20 confirmed cases without further spread. No approved vaccine or specific antiviral exists for the Bundibugyo strain; a Phase 2/3 trial of a strain-specific vaccine candidate began in Bunia, Ituri province in late October.

For readers in Cyprus and the broader eastern Mediterranean: the European Centre for Disease Prevention and Control continues to rate the risk to EU and EEA residents as very low, with no sustained transmission detected outside the DRC. Travellers connecting through US airports from Sunday should allow additional time at check-in.

Saturday, 1 November: H1N1 Flu Arrives Weeks Ahead of Schedule — 44 States Reporting Rising Activity

The CDC's FluView report for Week 42 (ending 24 October 2026) shows influenza activity running measurably above typical levels for this point in the calendar year, with 44 states reporting rising case counts. Preliminary CDC estimates place the toll so far at at least one million illnesses, 16,000 hospitalisations, and 900 deaths — all figures expected to climb substantially as the season progresses.

Subtyping data for the week ending 24 October show H1N1 accounting for 367 of 371 subtyped influenza A specimens — effectively 99%. Several reports link the early surge to a newly detected mutation in circulating H1N1, though CDC cautions it is too early to determine whether this mutation affects the effectiveness of this season's quadrivalent vaccine. CDC modelling forecasts continued increases in influenza-associated hospital admissions and emergency-department visits through at least the week ending 14 November.

For context, the 2025–26 season was classified as moderate-to-severe, ending with at least 26 million US illnesses and 21,000 deaths by February 2026. CDC recommends annual vaccination for everyone aged six months and older, and early antiviral treatment — oseltamivir or baloxavir — for higher-risk patients presenting with influenza-like illness. Clinicians in Cyprus and the region should note that ECDC's European respiratory surveillance typically begins to reflect Northern Hemisphere trends by late November, with Cyprus's own influenza peak usually arriving between December and February.

Tuesday, 29 October: NEJM Phase 2 Data — Repinatrabit Substantially Lowers Phenylalanine in Phenylketonuria Adults

The 29 October issue of the New England Journal of Medicine carries phase 2 randomised trial data for repinatrabit (Otsuka / Jnana Therapeutics), a selective oral inhibitor of the amino-acid transporter SLC6A19, in adults with phenylketonuria (PKU) whose plasma phenylalanine exceeded 600 µmol per litre at baseline. The trial reports a substantial reduction in plasma phenylalanine in the treatment arms compared with placebo, with no serious drug-related adverse events. Open-label extension data presented at the 2026 American College of Medical Genetics and Genomics meeting showed a mean 67% reduction in plasma Phe at Month 1 in adolescent participants — a signal consistent with the adult phase 2 result.

PKU is an autosomal recessive disorder in which defective phenylalanine hydroxylase allows phenylalanine to accumulate, causing progressive brain damage if uncontrolled from infancy. Existing treatments — a severely restricted low-Phe diet, BH4 co-factor therapy (sapropterin, effective only in patients with residual enzyme activity), and pegvaliase enzyme replacement — leave a meaningful proportion of patients inadequately controlled. Repinatrabit acts by blocking the intestinal transporter responsible for most dietary phenylalanine absorption, a mechanism theoretically effective regardless of underlying genotype.

The drug holds FDA Orphan Drug and Rare Pediatric Disease designations. A global Phase 3 trial, PheORD, is ongoing, with primary endpoint data expected in late 2026 or early 2027. If confirmed, repinatrabit would represent the first mechanistically new PKU treatment in more than a decade, and the first approach potentially effective across all genotypes.

Tuesday, 29 October: NEJM Review — β-Lactamases and Global Spread Drive the Gram-Negative Resistance Emergency

Also in the 29 October NEJM is a major review of gram-negative bacterial resistance covering the mechanisms of spread, the global epidemiology, and the narrowing therapeutic options for multidrug-resistant (MDR) infections. The review places β-lactamase production — extended-spectrum β-lactamases, KPC-type and OXA-type carbapenemases, and metallo-β-lactamases including NDM — at the centre of a crisis affecting Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa worldwide.

WHO estimates that 4.71 million deaths annually are closely associated with antimicrobial resistance; the toll from resistant Gram-negatives is highest in South and Southeast Asia, sub-Saharan Africa, and parts of the eastern Mediterranean. ECDC surveillance data show Cyprus and Greece among the EU member states with the highest rates of carbapenem-resistant Klebsiella — a pattern linked to higher carbapenem use, older hospital infrastructure, and cross-border healthcare traffic in the region.

The review acknowledges that newer β-lactam/β-lactamase inhibitor combinations — ceftazidime-avibactam, cefiderocol, imipenem-cilastatin-relebactam — extend effective coverage to many resistant isolates, but the authors stress that selective prescribing and robust antibiotic stewardship programmes are essential to preserve those agents' utility. Phage therapy and faecal microbiota transplantation are described as experimental adjuncts without a place in current routine guidelines. For clinicians and public-health planners in Cyprus and the eastern Mediterranean, the review is a timely reminder that the region's high carbapenem-resistant organism burden merits sustained investment in infection control, stewardship, and rapid diagnostic capacity.

Q4 2026 Watch: Asundexian — Bayer's Factor XIa Inhibitor for Secondary Stroke Prevention Nears FDA Decision

Bayer's asundexian, a first-in-class oral Factor XIa inhibitor, is under FDA Priority Review for the secondary prevention of ischaemic stroke and transient ischaemic attack (TIA), with a decision expected within the fourth quarter of 2026. The filing rests on the Phase 3 OCEANIC-STROKE trial, in which asundexian 50 mg once daily reduced the recurrence of ischaemic stroke from 8.4% to 6.2% versus placebo — a 26% relative reduction — in patients with non-cardioembolic ischaemic stroke or TIA.

Major bleeding occurred in 1.9% of asundexian-treated patients versus 1.7% on placebo, suggesting a substantially improved safety margin over direct oral anticoagulants currently used in atrial-fibrillation management. The mechanistic rationale: Factor XIa contributes to pathological clot formation but is less central to normal haemostasis than Factor Xa or thrombin, which is why blocking it may suppress thrombosis without proportionally increasing bleeding risk. Bayer has not disclosed a precise PDUFA target date; industry trackers place the decision before year end.

Ischaemic stroke is a leading cause of death and disability across Cyprus and the broader eastern Mediterranean, with incidence disproportionately high in older adults living with hypertension and type 2 diabetes. An approved Factor XIa inhibitor for secondary prevention would give neurologists and internists a new option with a differentiated bleeding profile relative to existing antiplatelet and anticoagulant regimens.

---

The content in this article is intended for general journalistic information only and does not constitute medical advice. Readers should consult a qualified healthcare clinician before making any changes to their treatment, medication, or health regimen.